| pubmed-article:14624153 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14624153 | lifeskim:mentions | umls-concept:C0021735 | lld:lifeskim |
| pubmed-article:14624153 | lifeskim:mentions | umls-concept:C0035525 | lld:lifeskim |
| pubmed-article:14624153 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:14624153 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:14624153 | lifeskim:mentions | umls-concept:C0332173 | lld:lifeskim |
| pubmed-article:14624153 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:14624153 | pubmed:dateCreated | 2003-11-18 | lld:pubmed |
| pubmed-article:14624153 | pubmed:abstractText | Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. Before pegylated interferons became available, higher and more frequent doses of interferon were expected to be more effective than the standard regimen of three million units thrice weekly. In fact, daily dosing is still proposed for non-pegylated interferon. The aim of this study was to compare the efficacy and safety of daily versus thrice-weekly interferon alfa-2b in combination with ribavirin as first-line treatment of chronic hepatitis C. | lld:pubmed |
| pubmed-article:14624153 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14624153 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14624153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14624153 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14624153 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:14624153 | pubmed:issn | 0954-691X | lld:pubmed |
| pubmed-article:14624153 | pubmed:author | pubmed-author:SchmiegelWolf... | lld:pubmed |
| pubmed-article:14624153 | pubmed:author | pubmed-author:ReiserMarkusM | lld:pubmed |
| pubmed-article:14624153 | pubmed:author | pubmed-author:GrossmannJoha... | lld:pubmed |
| pubmed-article:14624153 | pubmed:author | pubmed-author:WursthornKars... | lld:pubmed |
| pubmed-article:14624153 | pubmed:author | pubmed-author:BuggischPeter... | lld:pubmed |
| pubmed-article:14624153 | pubmed:author | pubmed-author:KoopKarstenK | lld:pubmed |
| pubmed-article:14624153 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14624153 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:14624153 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14624153 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14624153 | pubmed:pagination | 1299-304 | lld:pubmed |
| pubmed-article:14624153 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:meshHeading | pubmed-meshheading:14624153... | lld:pubmed |
| pubmed-article:14624153 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14624153 | pubmed:articleTitle | First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. | lld:pubmed |
| pubmed-article:14624153 | pubmed:affiliation | Department of Medicine, Ruhr-Universität Bochum (Knappschaftskrankenhaus), Germany. | lld:pubmed |
| pubmed-article:14624153 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14624153 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14624153 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:14624153 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:14624153 | pubmed:publicationType | Multicenter Study | lld:pubmed |
